US equities |
SPCX $167.97 ▲+5.67% NVDA $237.40 ▲+1.47% MU $1,068.79 ▼-0.57% TSLA $377.19 ▲+1.78% MSFT $526.36 ▲+1.71% INTC $116.92 ▼-2.02% SNDK $1,725.81 ▲+0.34% META $745.35 ▲+2.37%
FinancialContent

Silence Therapeutics Plc - American Depository Share (NQ:SLN)

10.20 -0.45 (-4.18%)
Delayed Quote Updated: 11:02 AM EDT, Oct 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Silence Therapeutics Plc - American Depository Share

< Previous 1 2 3 4 5 6 Next >
News headline image
Silence Therapeutics Presents Late-Breaking Phase 2 Zerlasiran Data at 2024 American Heart Association (AHA) Annual Meeting
From Silence Therapeutics plc
Via Business Wire
News headline image
Analyst Scoreboard: 4 Ratings For Silence Therapeutics ↗
 
Via Benzinga
News headline image
Silence Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
From Silence Therapeutics plc
Via Business Wire
News headline image
Analyst Expectations For Silence Therapeutics's Future ↗
 
Via Benzinga
News headline image
The Analyst Landscape: 6 Takes On Silence Therapeutics ↗
 
Via Benzinga
News headline image
What 7 Analyst Ratings Have To Say About Silence Therapeutics ↗
 
Via Benzinga
News headline image
Beyond The Numbers: 7 Analysts Discuss Silence Therapeutics Stock ↗
 
Via Benzinga
News headline image
Silence Therapeutics to Participate in Fireside Chat at the Jefferies London Healthcare Conference
From Silence Therapeutics plc
Via Business Wire
News headline image
Silence Therapeutics to Webcast Presentations at Upcoming September Investor Conferences
From Silence Therapeutics plc
Via Business Wire
News headline image
SLN Stock Earnings: Silence Therapeutics Reported Results for Q2 2024 ↗
Silence Therapeutics just reported results for the second quarter of 2024. 
Via InvestorPlace
News headline image
Silence Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
From Silence Therapeutics plc
Via Business Wire
News headline image
What 4 Analyst Ratings Have To Say About Silence Therapeutics ↗
 
Via Benzinga
News headline image
The 3 Best Gene Editing Stocks to Buy in August 2024 ↗
These are the best gene-editing stocks to buy as the biotechs pursue precision therapies to cure rare diseases. 
Via InvestorPlace
News headline image
Morgan Stanley Predicts Triple-Digit Rally for These 3 Stocks ↗
It takes a special set of circumstances for high-growth stocks to double in value in one year but analyst says these three can do it. 
Via InvestorPlace
News headline image
Silence Therapeutics Announces Positive Results from Ongoing SANRECO Phase 1 Study of Divesiran in Polycythemia Vera Patients
From Silence Therapeutics plc
Via Business Wire
News headline image
Silence Therapeutics Achieves $2 Million Research Milestone Payment from Hansoh Pharma Collaboration
From Silence Therapeutics plc
Via Business Wire
News headline image
Silence Therapeutics Announces Positive Topline 48-Week Data from Phase 2 Study of Zerlasiran in Patients with Elevated Lipoprotein(a)
From Silence Therapeutics plc
Via Business Wire
News headline image
Silence Therapeutics to Present at Jefferies Global Healthcare Conference
From Silence Therapeutics plc
Via Business Wire
News headline image
SLN Stock Earnings: Silence Therapeutics Reported Results for Q1 2024 ↗
Silence Therapeutics just reported results for the first quarter of 2024. 
Via InvestorPlace
News headline image
Silence Therapeutics Reports First Quarter 2024 Results and Highlights Pipeline Progress
From Silence Therapeutics plc
Via Business Wire
News headline image
Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright 2nd Annual BioConnect Investor Conference
From Silence Therapeutics plc
Via Business Wire
News headline image
Silence Therapeutics Announces Retirement of Alistair Gray from Board of Directors
From Silence Therapeutics plc
Via Business Wire
News headline image
3 Biotech Stocks to Turn $5,000 Into $1 Million: April 2024 ↗
Biotech stocks can offer some of the most explosive, exciting opportunities on the market.That is, if you find the right one. 
Via InvestorPlace
News headline image
Silence Therapeutics Announces JAMA Publication of Additional Phase 1 Data for Zerlasiran in Subjects with Elevated Lipoprotein(a)
From Silence Therapeutics plc
Via Business Wire
News headline image
7 Biotech Stocks Ready to Ride the Sector’s Resurgence ↗
With investors seeking new opportunities with certain segments appearing stretched, biotech stocks offer a viable canvas. 
Via InvestorPlace
News headline image
These Analysts Boost Their Forecasts On Silence Therapeutics After Full Year 2023 Results ↗
Silence Therapeutics Plc (NASDAQ: SLN) reported a loss for 2023 on Wednesday. 
Via Benzinga
News headline image
What's Going On With Silence Therapeutics Stock Today? ↗
Silence Therapeutics reports narrower Q4 loss, data from zerlasiran study, and strengthened cash position. In March 2024, Mallinckrodt notified Silence that they will not pursue further development of... 
Via Benzinga
News headline image
Silence Therapeutics Reports Full Year 2023 Financial Results and Recent Business Highlights
From Silence Therapeutics plc
Via Business Wire
News headline image
Silence Therapeutics Announces Positive Topline 36-Week Data from Ongoing Phase 2 Study of Zerlasiran in Patients with High Lipoprotein(a)
From Silence Therapeutics plc
Via Business Wire
News headline image
Earnings Scheduled For March 13, 2024 ↗
Companies Reporting Before The Bell • Sangamo Therapeutics (NASDAQ:SGMO) is likely to report quarterly loss at $0.26 per share on revenue of $8.10 million. 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >